Matching-adjusted indirect comparison (MAIC) of deucravacitinib versus adalimumab for the treatment of patients with moderate to severe plaque psoriasis over 2 years. J of Skin [Internet]. 2023 Mar. 13 [cited 2026 Apr. 29];7(2):s112. Available from: https://skin.dermsquared.com/skin/article/view/1995